Effect of Denosumab on Glucose Homeostasis in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors: A Pilot Study
Table 2
Parameters of glucose metabolism of the patients at baseline and one month after denosumab injection. Data are expressed as mean ± SD.
Baseline
1 month
value
Whole study population (n=14)
Serum glucose (mg/dl)
87.0 ± 8.7
83.8 ± 11.1
0.17
Serum insulin (μU/ml)
9.1 ± 6.4
8.5 ± 4.8
0.31
Log ΔAUC insulin (μU/ml/120 min)
7692 ± 4698
7795 ± 5244
0.90
HOMA-IR Index
2.0 ± 1.5
1.8 ± 1.1
0.27
Matsuda Index
5.8 ± 3.5
7.6 ± 8.6
0.26
QUICKI Index
0.362 ± 0.043
0.365 ± 0.042
0.51
Insulinogenic Index
0.8 ± 0.6
0.6 ± 0.5
0.45
Patients with HOMA-IR >2.5 (n=5)
Serum glucose (mg/dl)
90.6 ± 5.3
87.2 ± 4.9
0.44
Serum insulin (μU/ml)
16.3 ± 4.9
13.5 ± 3.5
0.029
Log ΔAUC insulin (μU/ml/120 min)
12429 ± 3883
12745 ± 4581
0.63
HOMA-IR Index
3.69 ± 1.29
2.89 ± 0.61
0.09
Matsuda Index
2.46 ± 0.71
2.65 ± 0.96
0.54
QUICKI Index
0.317 ± 0.013
0.327 ± 0.009
0.025
Insulinogenic Index
1.12 ± 0.95
0.82 ± 0.65
0.46
ΔAUC insulin, variation of area under the curve of insulin; HOMA-IR, homeostasis assessment model of insulin resistance; QUICKI, Quantitative Insulin Sensitivity Check Index.
